Standard Contracts
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 30th, 2022 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Daniel Soland (“you”) and Idera Pharmaceuticals, Inc., a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the “Company”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • August 14th, 2023 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Executive Transition and Separation Agreement (the “Agreement”) is made as of May 22, 2023 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Dr. Carl Morris (the “Executive”) (together, the “Parties”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 14th, 2022 • Tabula Rasa HealthCare, Inc. • Services-business services, nec • New Jersey
This Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Dr. Orsula V. Knowlton (“you”) and Tabula Rasa Healthcare, Inc. (together with its wholly owned subsidiaries and affiliates, the “Company”).
ContractExecutive Transition and Separation Agreement • May 5th, 2020 • California
EX-10.1 2 exhibit101executivetransit.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement (“Agreement”), dated as of the 31st day of May, 2014, is by and between Advanced Energy Industries, Inc., a Delaware corporation (“AEI”) and Garry Rogerson, an individual (“Executive” and, together with AEI, the “Parties”). RECITALS A.Executive is employed full time as the Chief Executive Officer (“CEO”) of AEI. B.Executive serves at the pleasure of the Board of Directors (“Board”), and his employment may be terminated by the Company or by Executive at any time. C.The Parties desire to provide for a transition period and termination of Executive’s employment with AEI in an amicable and orderly way, to provide for an orderly search for, engagement of, and transition to, a new CEO, and to settle any and all disputes, known and unknown, in accordance with the terms and conditions set forth in this Agreement. In consideration of
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • January 3rd, 2020 • Alliance Data Systems Corp • Services-business services, nec • Texas
This Executive Transition and Separation Agreement (the “Separation Agreement”) is made as of December 20, 2019 by and among Alliance Data Systems Corporation, ADS Alliance Data Systems, Inc. (together, the “Company”) and Melisa A. Miller (“Executive”) (collectively, the “Parties”).
AMENDMENT NO. 1 TO EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • April 13th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Amendment No. 1 to Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Vincent Milano (“You”) and Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the “Company”). You and the Company are collectively referred to as the “Parties” throughout this Agreement.
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Executive Transition and Separation Agreement (the “Agreement”) is made as of September 29, 2022 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Erin Powers Brennan (the “Executive”) (together, the “Parties”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • November 18th, 2014 • Advanced Energy Industries Inc • Electronic components, nec • Colorado
This Executive Transition and Separation Agreement (“Agreement”), dated as of November 17, 2014, is by and between Advanced Energy Industries, Inc., a Delaware corporation (“AEI”) and Danny C. Herron, an individual (“Executive” and, together with AEI, the “Parties”).
AMENDMENT NO. 1 TO EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • April 13th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Amendment No. 1 to Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Daniel Soland (“You”) and Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the “Company”). You and the Company are collectively referred to as the “Parties” throughout this Agreement.
EXECUTIVE TRANSITION AND SEPARATION AGREEMENT AND GENERAL RELEASEExecutive Transition and Separation Agreement • October 5th, 2016 • Rennova Health, Inc. • Services-testing laboratories • Delaware
This Executive Transition and Separation Agreement and General Release ("Agreement") is by and among Rennova Health, Inc. and Medytox Solutions, Inc. (collectively, the "Company"), and Jason P. Adams ("Executive"), and will become effective upon the 8th day after execution by the Executive, if not revoked, as set forth in Section 12 below.
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • January 19th, 2022 • DoubleVerify Holdings, Inc. • Services-computer programming, data processing, etc.
This EXECUTIVE TRANSITION AND SEPARATION AGREEMENT (the “Agreement”), dated as of January 14, 2022 (the “Effective Date”), is entered into by and among Matthew McLaughlin (“Executive”), DoubleVerify Inc., a Delaware corporation (the “Company”) and solely for purposes of Section 1(e), DoubleVerify Holdings, Inc., a Delaware corporation (“Holdings”, and, together with Executive and the Company, the “Parties”). Any term capitalized but not defined in this Agreement will have the meaning set forth in the Employment Agreement between Executive and the Company, dated as of December 31, 2020 (the “Employment Agreement”).
